Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. LNSR
LNSR logo

LNSR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
11.740
Open
11.690
VWAP
11.67
Vol
57.43K
Mkt Cap
139.45M
Low
11.580
Amount
669.94K
EV/EBITDA(TTM)
--
Total Shares
11.94M
EV
137.74M
EV/OCF(TTM)
--
P/S(TTM)
2.36
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Show More

Events Timeline

(ET)
2025-11-06
07:07:32
Lensar Announces Q3 Earnings Per Share of 31 Cents Compared to 13 Cents Last Year
select
2025-08-07 (ET)
2025-08-07
07:35:36
Lensar reports Q2 EPS (15c) vs (79c) last year
select
2025-05-08 (ET)
2025-05-08
07:24:52
Lensar reports Q1 EPS ($2.32) vs. (19c) last year
select
2025-03-24 (ET)
2025-03-24
08:08:59
Alcon to acquire Lensar for $14.00 per share in cash
select
2025-03-24
08:05:42
Alcon to acquire Lensar for $430M
select

News

Newsfilter
8.5
02-25Newsfilter
LENSAR Provides Update on Alcon Acquisition Status
  • Acquisition Update: LENSAR is cooperating with the FTC regarding its request for additional information related to the acquisition by Alcon, with expectations to close the transaction in the first half of 2026, contingent upon regulatory approvals.
  • Technological Innovation: The ALLY Robotic Cataract Laser System integrates a fast dual-modality laser and AI, aimed at enhancing surgical efficiency and reducing operational costs, thereby strengthening LENSAR's market position in the competitive medical device sector.
  • Market Risks: While the transaction is anticipated to close, various risk factors exist, including potential delays in regulatory approvals that could adversely affect the company's operational results and stock price, increasing uncertainty for investors.
  • Future Outlook: The company emphasizes that all forward-looking statements are subject to numerous known and unknown risks, and actual results may differ materially from expectations, urging investors to carefully assess the associated risks.
Newsfilter
5.0
2025-08-19Newsfilter
Elizabeth O'Farrell Joins the Board of Directors at SpyGlass Pharma
  • Appointment Announcement: SpyGlass Pharma has appointed Elizabeth O'Farrell as an Independent Director and Chair of the Audit Committee, effective immediately.

  • Experience and Role: Ms. O'Farrell brings over 30 years of experience in strategic planning, financial optimization, and regulatory compliance, which will aid SpyGlass in advancing its Drug Delivery Platform through pivotal Phase 3 trials.

  • Background: O'Farrell previously held several executive roles at Eli Lilly, including CFO and Chief Procurement Officer, and currently serves on multiple boards, providing her with extensive finance and operational expertise.

  • SpyGlass Pharma Overview: The company is focused on developing a controlled release drug delivery platform for glaucoma management, aiming for FDA approval after successful clinical trials.

Globenewswire
5.0
2025-08-19Globenewswire
Elizabeth O’Farrell Joins the Board of Directors at SpyGlass Pharma
  • Appointment Announcement: SpyGlass Pharma has appointed Elizabeth (Liz) O’Farrell as an Independent Director and Chair of the Audit Committee, effective immediately.

  • Experience and Role: Ms. O’Farrell brings over 30 years of experience in strategic planning, financial optimization, and regulatory compliance, which will aid SpyGlass as it advances its Drug Delivery Platform into Phase 3 trials.

  • Background: She previously held various executive positions at Eli Lilly, including CFO of Lilly USA and Chief Procurement Officer, and currently serves on multiple boards, providing valuable insights to those organizations.

  • SpyGlass Pharma Overview: The company is focused on developing a controlled release drug delivery platform for glaucoma management, with plans to share follow-up data from its studies at an upcoming ophthalmology meeting.

Globenewswire
7.0
2025-06-15Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating LENSAR, Atai Life Sciences, and iCAD for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.

  • Legal Support for Shareholders: The firm offers free consultations to shareholders regarding their legal rights and options, emphasizing that they operate on a contingent fee basis with no upfront costs for clients.

Globenewswire
7.0
2025-06-15Globenewswire
HAPPY FATHER’S DAY and $HARHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: SVT, SSBK, LNSR, iCAD
  • Class Action Firm Recognition: Monteverde & Associates PC, a top class action firm based in New York, is investigating several proposed mergers involving companies like Servotronics, Southern States Bancshares, LENSAR, and iCAD, with specific shareholder actions and deadlines outlined for each case.

  • Legal Services Offered: The firm emphasizes its successful track record in recovering funds for shareholders and invites individuals with concerns regarding the listed companies to seek free information or legal assistance.

Globenewswire
7.0
2025-06-09Globenewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders
  • Investigation of Companies: Halper Sadeh LLC is investigating potential violations of federal securities laws related to the sales of several companies, including Servotronics, LENSAR, iCAD, and Southern States Bancshares, urging shareholders to explore their legal rights and options.

  • Legal Support for Shareholders: The law firm offers to represent shareholders on a contingent fee basis, meaning no upfront costs for legal fees, while aiming to secure increased compensation or additional disclosures from the proposed transactions.

Wall Street analysts forecast LNSR stock price to rise
2 Analyst Rating
Wall Street analysts forecast LNSR stock price to rise
0 Buy
2 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
15.00
Averages
15.00
High
15.00
Current: 0.000
sliders
Low
15.00
Averages
15.00
High
15.00
Lake Street
Frank Takkinen
Strong Buy
to
Hold
Downgrades
$16 → $15
AI Analysis
2025-03-24
Reason
Lake Street
Frank Takkinen
Price Target
$16 → $15
AI Analysis
2025-03-24
Downgrades
Strong Buy
to
Hold
Reason
Lake Street analyst Frank Takkinen downgraded Lensar (LNSR) to Hold from Buy with a price target of $15, down from $16, after Alcon (ALC) announced the acquisition of Lensar for $14.00 per share in cash, with an additional contingent value right of up to $2.75 per share tied to procedure-based milestones. The firm expects the acquisition to close as is, given the "reasonable valuation," but if a higher bid came in it would expect it would need to be $18-plus per share.

Valuation Metrics

The current forward P/E ratio for LENSAR Inc (LNSR.O) is -89.31, compared to its 5-year average forward P/E of -13.56. For a more detailed relative valuation and DCF analysis to assess LENSAR Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.56
Current PE
-89.31
Overvalued PE
8.93
Undervalued PE
-36.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
4.37
Current EV/EBITDA
48.59
Overvalued EV/EBITDA
80.73
Undervalued EV/EBITDA
-72.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.48
Current PS
1.76
Overvalued PS
2.12
Undervalued PS
0.84

Financials

AI Analysis
Annual
Quarterly

Whales Holding LNSR

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is LENSAR Inc (LNSR) stock price today?

The current price of LNSR is 11.675 USD — it has decreased -0.98

What is LENSAR Inc (LNSR)'s business?

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

What is the price predicton of LNSR Stock?

Wall Street analysts forecast LNSR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNSR is15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is LENSAR Inc (LNSR)'s revenue for the last quarter?

LENSAR Inc revenue for the last quarter amounts to 14.32M USD, increased 5.74

What is LENSAR Inc (LNSR)'s earnings per share (EPS) for the last quarter?

LENSAR Inc. EPS for the last quarter amounts to -0.31 USD, increased 138.46

How many employees does LENSAR Inc (LNSR). have?

LENSAR Inc (LNSR) has 140 emplpoyees as of March 13 2026.

What is LENSAR Inc (LNSR) market cap?

Today LNSR has the market capitalization of 139.45M USD.